Radiofrequency Microneedling Patents: Leaders & Filing Trends 2026
- 76.7% concentration. The top 5 of 14 ranked assignees account for 23 of the 30 records in scope — filing here is a small-club affair, not a fragmented field.
- Filings cooled after 2021. The peak year was 2021 at 9 records; by 2024, the last complete filing year, activity had dropped to 2 — a 78% decline over that span.
- Diagnosis and surgery claims dominate. A61B covers 53.3% of the 30 records, ahead of medicinal preparations (40.0%) and electrotherapy (33.3%), showing where the claim density actually sits.
Filing growth compares 2021 (9 records) with 2024 (2) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 30 records in scope (CR5), not by the ranked leaders only.
What the radiofrequency microneedling patent record shows
Radiofrequency microneedling devices combine mechanical needle penetration with localized RF energy delivery to induce controlled dermal coagulation and collagen remodeling. The patent record in scope spans 2015 to mid-2026 and covers 30 published records tied to needle depth control, insulated needle design, pulse energy delivery, coagulation zone management, and skin-type safety considerations. Filing activity clustered heavily around a small set of assignees, with device claims concentrated in surgical/diagnostic and electrotherapy classifications rather than pure cosmetic-use categories.
The filing curve rose through the late 2010s, peaked in 2021, and has since declined through the last complete filing year. Because publication typically lags filing by roughly 18 months, the most recent years in the trend understate actual filing activity and should not be read as a sign the technology has stalled.
Filing trend and technology composition
The two views below cover the same 30 records in scope: one tracks when filings happened, the other shows which technical classes those filings sit in. Because a single record can carry more than one IPC class, the composition shares add up to more than 100%.
A sharp rise to 2021, then a pullback
Filing volume climbed from a single record in 2017 to a peak of 9 in 2021, then fell to 2 by 2024 — a 78% drop over that three-year span. Treat 2025 and 2026 figures as incomplete rather than as evidence of a continued decline, since publication lag has not yet caught up with recent filing activity.
Claim density sits in diagnosis, surgery and electrotherapy
A61B (diagnosis & surgery) appears in 53.3% of the 30 records, the single largest technical footprint, followed by A61K (medicinal preparations) at 40.0% and A61N (electrotherapy & radiation therapy) at 33.3%. Sterilising/disinfecting (A61L) and body-fluid devices (A61M) each sit at 30.0%, while cosmetics-use classification (A61Q) covers just 3.3% of records — a narrow footprint given how the devices are marketed.
Shares are the percentage of the 30 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Radiofrequency Microneedling Devices with Eureka
This page is one run against one query. Ask Eureka your own question about radiofrequency microneedling devices and every answer comes back with the patent numbers behind it.
Try EurekaMost-cited records and a representative filing
Uniform diffusion of radiofrequency heating by electrode array (US20220054189A1)
A microneedling system reciprocates a plurality of microneedles on a handpiece into the skin, with positive and negative electrodes arranged across an array so each electrode sits adjacent to a closest electrode of opposite polarity, including configurations with an uneven electrode count and central electrodes surrounded by at least three opposite-polarity neighbours. The arrangement is designed to deliver RF energy for collagen coagulation and regeneration while controlling how heat diffuses across the treatment area.Filed by Aesthetics Biomedical, Inc., published 2022-02-24.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20190046479A1 | Methods, compositions, and devices for drug / live cell microarrays | 55 |
| 2 | EP2312997A1 | Devices and methods for percutaneous energy delivery | 43 |
| 3 | US20170112568A1 | Radio frequency handpiece for medical treatments | 33 |
| 4 | US20220054189A1 | Uniform diffusion of radiofrequency heating by electrode array | 28 |
| 5 | WO2018017674A1 | Methods, compositions, and devices for drug / live cell microarrays | 20 |
| 6 | US20200230081A1 | Methods, compositions, and devices for drug / live cell microarrays | 11 |
| 7 | US10624865B2 | Methods, compositions, and devices for drug/live cell microarrays | 11 |
| 8 | WO2010009150A1 | Devices and methods for percutaneous energy delivery | 10 |
| 9 | WO2020223542A1 | Uniform diffusion of radiofrequency heating by electrode array | 8 |
| 10 | US20210275472A1 | Methods, compositions, and devices for drug / live cell microarrays | 6 |
Citation counts reflect influence within the searched corpus and skew toward older filings; they are not a measure of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for a filing decision
Three figures from this dataset matter more than the rest for anyone deciding where to file or which prior art to watch.
A small group holds most of the claim space
With 14 assignees ranked and the top 5 already covering 23 of the 30 records in scope, this is not a fragmented emerging field — it behaves like a mature niche where a handful of players set the terms for electrode arrangement, needle insulation and pulse control.
Peak filing has passed, but the picture is incomplete
The field peaked at 9 records in 2021 and had fallen to 2 by 2024, the last complete filing year. Given the roughly 18-month publication lag, 2025-2026 figures are not yet reliable evidence of a continued slowdown.
Device and procedural claims outweigh pure cosmetic framing
More records sit in diagnosis/surgery (A61B) and electrotherapy (A61N) classifications than in cosmetics use (A61Q, just 3.3%), which suggests defensible claim positions have historically been built around delivery mechanism and safety control rather than aesthetic outcome.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to radiofrequency microneedling devices, with the prior art for and against each one.
Who is filing, and where the gaps sit
The ranked assignee list contains 14 companies and individual inventors, all counted in records — this is the complete ranking the dataset returns, not a filtered top-N list. Recent-year momentum across the leading names is flat: the assignees with the deepest historical filing counts show 0 records in the latest year, consistent with the broader 2021-to-2024 pullback rather than any single company exiting the space.
One assignee anchors the field
The leading assignee holds 9 of the 30 records in scope, nearly a third of the entire dataset on its own, with claim coverage spanning device and delivery mechanism categories.
Co-assignment is limited but concentrated
Only 6 co-assignee pairs appear across the dataset, with the strongest links all tracing back to Primaeva Medical Inc alongside individual named inventors — a pattern more typical of inventor-founder filings than broad corporate partnerships.
Filing is US-centric with a PCT and EPO tail
The United States receives 14 of the records in scope, ahead of WIPO/PCT filings at 7 and EPO filings at 5, with single filings recorded in Austria, Germany and India — a footprint that favours US-first prosecution strategy.
| Assignee | Recent year | YoY |
|---|---|---|
| PATHAK HOLDINGS LLC | 0 | — |
| Candela Corp | 0 | — |
| PRIMAEVA MEDICAL INC | 0 | — |
| The General Hospital Corp | 0 | — |
| Syneron Medical Ltd | 0 | — |
| EPSTEIN WENDY | 0 | — |
| DURAIRAJ KALPNA KAY | 0 | -100% |
| AESTHETICS BIOMEDICAL INC | 0 | — |
Where to take this next
The dataset points to a concentrated but cooling field with specific technical gaps still open. These next steps help translate the landscape into a filing or freedom-to-operate decision.
Map claim boundaries around the leading assignee
With one assignee holding 9 of 30 records, understanding exactly which electrode-array and needle-insulation claims that portfolio covers is the first step before drafting adjacent claims.
Explore assignee portfoliosTest white space in skin-type-adaptive control
Cosmetics-use classification and adaptive pulse calibration remain thin in this dataset, suggesting room for narrowly drafted claims that connect skin-type safety data to real-time energy adjustment.
Run a white space searchWatch for the 2025-2026 filing catch-up
Because publication lags filing by roughly 18 months, the apparent decline after 2021 needs re-checking once 2025 and 2026 filings finish publishing before drawing conclusions about the field's trajectory.
Track filing trendsCommon questions about radiofrequency microneedling patents
One assignee leads the ranked field with 9 of the 30 records in scope, close to a third of the entire dataset by itself. The top 5 of 14 ranked assignees together account for 23 records, or 76.7% of all records in scope, meaning ownership is concentrated in a small group rather than spread evenly. Anyone evaluating freedom to operate should start by mapping that leading portfolio's specific claims on needle configuration and energy delivery before assuming the space is open.
Filing activity peaked in 2021 at 9 records and had fallen to 2 by 2024, the last complete filing year, a 78% decline over that span. However, publication typically lags filing by roughly 18 months, so 2025 and 2026 figures in any dataset are still incomplete and should not be read as proof the field has stopped growing. A fair read is that the initial wave of core device claims has been filed, and any renewed growth would likely show up in classes not yet heavily claimed.
The dataset's IPC composition shows diagnosis and surgery (A61B) as the largest category at 53.3% of the 30 records, followed by medicinal preparations (A61K) at 40.0% and electrotherapy/radiation therapy (A61N) at 33.3%. Sterilising and body-fluid device classes each cover 30.0% of records, while cosmetics-use classification (A61Q) covers only 3.3%. This distribution indicates that most defensible claims have historically centered on the delivery mechanism and safety controls rather than the cosmetic outcome itself.
US20220054189A1, assigned to Aesthetics Biomedical, Inc. and published in 2022, claims a specific electrode-array arrangement where each electrode sits adjacent to a closest electrode of opposite polarity, including configurations with an uneven electrode count and central electrodes surrounded by at least three opposite-polarity neighbours. That is a narrow geometric claim on electrode placement, not a claim over RF microneedling broadly. A new entrant using a different electrode topology, needle-insulation approach, or pulse-timing scheme would likely sit outside this specific claim scope, but should still check it directly against any planned electrode layout.
Based on this dataset, cosmetics-use classification (A61Q) sits at just 3.3% of records, and adjacent areas like skin-type-adaptive pulse calibration and coagulation zone imaging integration appear thin relative to the dense A61B and A61N core. That gap suggests opportunity for claims that tie real-time skin-type safety data to adaptive energy delivery, an area not yet crowded by the leading assignees' core electrode and needle-depth claims. Any such claim should still be checked against the leading portfolio's broader device-level coverage before filing.
Research Radiofrequency Microneedling Devices in depth with Eureka
Go past this page: query the whole radiofrequency microneedling devices corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.